Saniona AB: Saniona reports encouraging start for tesofensine Phase 3 study (GlobeNewswire)
"Saniona, a leading biotech company in the field of ion channels, today announces that Saniona's partner, Medix, has recruited 150 out of the planned 372 patients in the study during the first six weeks."
"Saniona, a leading biotech company in the field of ion channels, today announces that it has reached the third research milestone for identifying new drug candidates for the treatment of Parkinson's disease, which is supported by The Michael J. Fox Foundation for Parkinson's Research (MJFF)."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.